Bovine virus vaccines that are liquid stable
The present invention discloses liquid stable bovine vaccines that comprise a live attenuated virus, and a sugar alcohol. The present invention also discloses the manufacture of such vaccines and methods of protecting an animal by administration of such vaccines.
1. A liquid stable vaccine that comprises a live attenuated bovine respiratory coronavirus (BRCV), a 5-40% (w/v) sugar alcohol, and 0.15 to 0.75 M of an amino acid selected from the group consisting of arginine, glutamic acid, glycine, and any combination thereof; wherein the liquid stable vaccine has a pH of 6.0 to 8.0.
2. The liquid stable vaccine of claim 1 wherein the sugar alcohol is sorbitol.
3. The liquid stable vaccine of claim 2 wherein the amino acid is arginine.
4. The liquid stable vaccine of claim 3 , further comprising a live attenuated bovine virus is selected from the group consisting of a bovine viral diarrhea virus (BVDV), infectious bovine rinotracheitis virus (IBR), parainfluenza type 3 virus (PI3), bovine respiratory syncytial virus (BRSV), and any combination thereof; and wherein the live attenuated BVDV is selected from the group consisting of BVDV1, BVDV2, and BVDV1 and BVDV2.
5. The liquid stable vaccine of claim 3 that further comprises a killed bovine virus.
6. The liquid stable vaccine of claim 3 that further comprises a bacterium.
7. The liquid stable vaccine of claim 6 wherein the bacterium is selected from the group consisting of a live attenuated Pasteurella multocida , a live attenuated Mannheimia haemolytica , a live attenuated Histophilus somni , a live attenuated Mycoplasma bovis , a killed Pasteurella multocida , a killed Mannheimia haemolytica , a killed Histophilus somni , a killed Mycoplasma bovis , and any combination thereof.
8. The liquid stable vaccine of claim 1 further comprising a sugar additive that is a non-alcohol sugar, wherein the total amount of the sugar alcohol and the non-alcohol sugar in the liquid stable vaccine is 10-40% (w/v).
9. The liquid stable vaccine of claim 1 wherein the non-alcohol sugar is selected form the group consisting of sucrose and trehalose.
10. The liquid stable vaccine of claim 1 that further comprises a component selected from the group consisting of an antioxidant, a surfactant, and a chelator.
11. The liquid stable vaccine of claim 1 that further comprises a buffer.
12. The liquid stable vaccine of claim 11 wherein the buffer comprises 2.5 to 50 mM potassium phosphate.
13. The liquid stable vaccine of claim 1 , wherein the amino acid is arginine.
14. The liquid stable vaccine of claim 13 , further comprising a live attenuated bovine viral diarrhea virus (BVDV), and a live attenuated infectious bovine rinotracheitis virus (IBR); and wherein the live attenuated BVDV is selected from the group consisting of BVDV1, BVDV2, and BVDV1 and BVDV2.
15. The liquid stable vaccine of claim 14 , that further comprises, a live attenuated PI3 and a live attenuated BRSV.
16. A method of vaccinating a bovine against bovine viral diarrhea virus (BVDV), infectious bovine rinotracheitis (IBR) virus, parainfluenza type 3 (PI3), bovine respiratory syncytial virus (BRSV), and bovine respiratory coronavirus (BRCV) comprising administering to the bovine the liquid stable vaccine of claim 15 .
17. The method of claim 16 , wherein said administering is performed by subcutaneous injection.
18. A method of vaccinating a bovine against bovine respiratory coronavirus (BRCV) comprising administering to the bovine the liquid stable vaccine of claim 1 .
19. The method of claim 18 , wherein said administering is performed by subcutaneous injection.
20. A method of making a liquid stable vaccine that comprises combining a therapeutically effective amount of a live attenuated bovine respiratory coronavirus (BRCV) with a 5-40% (w/v) sugar alcohol, and 0.15 to 0.75 M arginine; wherein the liquid stable vaccine has a pH of 6.0 to 8.0.